Physician profile
Anna C Asher
NPI 1497767545
$8,847.12
in general payments reported to CMS, 2019-2025
34 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $661 · 2021: $1,238 · 2022: $1,535 · 2023: $1,537 · 2024: $1,551 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,245.76 |
| Education | $294.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,691.59 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $1,412.78 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $739.67 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $695.85 | 2019-2025 | Dupixent |
| Ucb, INC. | $489.99 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $391.71 | 2019-2025 | Adbry |
| Janssen Biotech, INC. | $385.33 | 2021-2025 | Tremfya |
| Pfizer INC. | $372.21 | 2019-2025 | |
| Galderma Laboratories, L.P. | $314.94 | 2019-2025 | Nemluvio |
| Amgen INC. | $309.59 | 2019-2024 | Otezla, Enbrel |
| Lilly USA, LLC | $301.67 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $298.65 | 2021-2025 | Opzelura |
| Almirall LLC | $202.99 | 2020-2023 | Klisyri, Seysara |
| Allergan, INC. | $176.76 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $126.95 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $92.13 | 2020-2021 | |
| Genzyme Corporation | $88.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.22 | 2021-2024 | Spevigo |
| Mallinckrodt Hospital Products INC. | $76.81 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $76.69 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $74.18 | 2023-2024 | Sotyktu |
| Journey Medical Corporation | $68.74 | 2021-2025 | |
| Dermavant Sciences, INC. | $67.84 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.93 | 2019-2022 | |
| Revance Therapeutics, INC. | $62.48 | 2025 | Daxxify |
| Mission Pharmacal Company | $29.76 | 2019-2021 | |
| Hill Dermaceuticals, INC. | $26.06 | 2024 | Tolak |
| Biofrontera INC. | $25.62 | 2020-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Prugen, INC. Pharmaceuticals | $22.54 | 2020 | |
| Celgene Corporation | $22.26 | 2019 | |
| Botanix Sb INC | $18.09 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $11.60 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.42 | 2019 | |
| Organon LLC | $11.25 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.